Compare TWIN & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWIN | AKBA |
|---|---|---|
| Founded | 1918 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 320.9M | 343.4M |
| IPO Year | 1994 | 2014 |
| Metric | TWIN | AKBA |
|---|---|---|
| Price | $24.85 | $0.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.67 |
| AVG Volume (30 Days) | 77.6K | ★ 3.9M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.98% | N/A |
| EPS Growth | N/A | ★ 93.94 |
| EPS | ★ 1.76 | N/A |
| Revenue | ★ $340,738,000.00 | N/A |
| Revenue This Year | $10.79 | N/A |
| Revenue Next Year | $8.43 | N/A |
| P/E Ratio | $14.18 | ★ N/A |
| Revenue Growth | ★ 15.45 | N/A |
| 52 Week Low | $8.50 | $0.81 |
| 52 Week High | $25.30 | $3.32 |
| Indicator | TWIN | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 60.09 | 29.48 |
| Support Level | $14.76 | $0.85 |
| Resistance Level | N/A | $1.54 |
| Average True Range (ATR) | 0.98 | 0.07 |
| MACD | 0.06 | -0.04 |
| Stochastic Oscillator | 80.74 | 7.33 |
Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.